Indications and effects of ibrutinib

Ibrutinib, an oral small molecule BTK (Bruton’s tyrosine kinase) inhibitor, has proven its excellent therapeutic potential in multiple clinical studies, especially in the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and Waldenstrom’s macroglobulinemia (WM) in adults. This article will introduce the specific indications and effects of ibrutinib.

First of all, ibrutinib provides an important treatment path for adult patients with CLL/SLL, especially those carrying chromosome 17 deletion (17p deletion). Since these patients do not respond well to traditional chemotherapy drugs, the introduction of ibrutinib brings them new hope. By precisely inhibiting the activity of BTK, it effectively blocks the abnormal proliferation and survival of B cells, thereby significantly extending the progression-free survival (PFS) and overall survival (OS) of patients.

Secondly, in the treatment of adultsWM, ibrutinib also shows excellent efficacy. WM, as a rare B-cell lymphoma, is often accompanied by an increase in monoclonal immunoglobulin M (IgM) in the serum. Ibrutinib can specifically inhibit BTK, effectively control the progression of WM, alleviate patients' symptoms, and improve their quality of life.

In addition, ibrutinib has shown potential in the treatment of chronic graft-versus-host disease (GVHD). GVHD is a common serious complication after organ transplantation that may lead to transplant failure and patient death. For GVHD patients aged 1 year and above who have failed one or more systemic treatments, ibrutinib helps relieve the symptoms of GVHD by regulating the function of the immune system and provides patients with new treatment options.

In summary, ibrutinib has shown significant efficacy in the treatment ofCLL/SLL, WM and GVHD, bringing new hope to eligible patients. Currently, the drug is available in China, and patients can consult local pharmacies for specific selling prices. At the same time, there are also affordable generic drugs available overseas, providing patients with more diverse treatment options.